Nuvectis Pharma announces publication in JEM for NXP900

Nuvectis Pharma announced a publication in the Journal of Experimental Medicine, JEM, for NXP900 in an in-vivo model of metastatic castration resistant prostate cancer, mCRPC, with acquired resistance to enzalutamide, the active ingredient in XTANDI. "This publication adds encouraging new data to the substantial body of evidence supporting the clinical potential of NXP900," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Bentsur continued, "Led by top scientists and published in a leading scientific journal, the research, which highlights NXP900’s potential to reverse XTANDI resistance when dosed in combination with XTANDI, also highlights the relationship between the effects seen in the enzalutamide-resistant mCRPC model to NXP900’s mechanism of action. Based on all the evidence generated to date, we believe that NXP900 has the potential to become a best-in-class SRC/YES1 kinase inhibitor with potential utility in a range of solid tumor cancers and we look forward to unlocking its therapeutic potential in the clinic."